Rifampin decreases the plasma concentrations and effects of repaglinide

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 5, 2000, Pages 495-500

  Niemi, Mikko ^a   Backman, Janne T ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a   Kivistö, Kari T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; REPAGLINIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CARBAMATES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIXED FUNCTION OXYGENASES; PIPERIDINES; RIFAMPIN;

EID: 0033711566     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.111183     Document Type: Article

References (23)

1. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus
2. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers
3. Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing
4. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6 and CYP3A by H2-receptor antagonists
5. Drug interaction studies with repaglinide: Repaglinide on digoxin or theophylline pharmacokinetics and cimetidine on repaglinide pharmacokinetics
6. Pharmacokinetic drug interactions with rifampicin
7. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
8. Update on rifampin drug interactions, III
9. Triazolam is ineffective in patients taking rifampin
10. Rifampin reduces plasma concentrations and effects of zolpidem
11. Concentrations and effects of buspirone are considerably reduced by rifampicin
12. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
13. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
14. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
15. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
16. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
17. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
18. Drug interactions in epilepsy
19. Second thoughts about safety of St John's wort
20. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin
21. Indinavir concentrations and St John's wort
22. Repaglinide pharmacokinetics in healthy young adult and elderly, subjects
23. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin